Table of Contents
Trial overview
The provided trial is an interventional study, which means researchers assigned treatments to study participants instead of only observing them.[1] It was designed to assess the clinical efficacy and safety of ANB032 in people with moderate to severe atopic dermatitis, and Alclometasone Dipropionate was one of the study treatments listed.[1]
Who was studied
The target condition was atopic dermatitis, a long-lasting itchy skin disease also known as eczema.[1] The study focused on subjects with moderate to severe disease, so it was not aimed at mild cases.[1]
Treatments in the study
The study compared several treatments: placebo matching the investigational product, ANB032 given by subcutaneous injection, hydrocortisone for cutaneous use, and Alclometasone Dipropionate for cutaneous use.[1] A placebo is a look-alike treatment that does not contain the active study drug, and cutaneous use means use on the skin.[1]
Because Alclometasone Dipropionate was included among the study interventions, the trial data show it as part of a broader comparison of skin treatments in atopic dermatitis.[1]
What was measured
The main endpoint was the mean change from baseline in Eczema Area and Severity Index (EASI) at Week 14.[1] Baseline means the starting point before treatment, and EASI is a score used to measure how severe eczema is and how much skin is affected.[1]
Trial status and size
The trial phase was Phase 2, which is a stage that usually looks more closely at whether a treatment may work and continues safety checking.[1] The planned enrollment was 160 people, but the study status was Withdrawn, meaning it was stopped before completion.[1]
